MICHAEL SCHULTZ: Open Payments
NPI 1396727533 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,000 in 95 payments from 15 companies in 2025. Trend: 2023 $1,033 · 2024 $1,864 · 2025 $2,000
Food & beverage: $1,980Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $681 |
| Janssen Biotech, Inc. | 11 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $220 |
| Ardelyx, Inc. | 9 | $181 |
| Phathom Pharmaceuticals, Inc. | 5 | $116 |
| PFIZER INC. | 6 | $110 |
| Madrigal Pharmaceuticals | 3 | $98 |
| Gilead Sciences, Inc. | 5 | $92 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| VIVUS LLC | 3 | $64 |
Products named: RINVOQ, TREMFYA, ENTYVIO, IBSRELA, LINZESS, VOQUEZNA, SKYRIZI, REZDIFFRA.
Industry payments across CT — which companies pay providers there.
